Episode 55: Developing a Maternal RSV Vaccine

Published on: 
,

Pharmaceutical Executive

Kathrin Jansen, Senior Vice President and Head of Vaccine Research and Development at Pfizer, talks about the challenges of creating a new maternal vaccine for respiratory syncytial virus, also known as RSV, currently being administered to pregnant women in trials, in the hopes of protecting their infants.

Kathrin Jansen, Senior Vice President and Head of Vaccine Research and Development at Pfizer, talks about the challenges of creating a new maternal vaccine for respiratory syncytial virus, also known as RSV,  currently being administered to pregnant women in trials, in the hopes of protecting their infants.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.

Advertisement

Pharmaceutical Executive Magazine

·

Episode 55: Developing a Maternal RSV Vaccine

 

Related Content:

Editorial Podcasts
Avoiding Commercialization Pitfalls for CGTs
Ethical AI Practices
Drug Pricing Challenges and Navigating the IRA